

Form PTO-1449
(Rev. 8-88)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

Serial No.

6193/1

61972,463

Applicant

Pena *et al.*

Filing Date

February 5, 2002

Gross No.

Unknown

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
UD	AA	3,086,912	Apr 23, 1963	Bergy <i>et al.</i>	167	65	
	AB	3,282,780	Nov 01, 1966	Martin	167	65	
	AC	3,300,475	Jan 24, 1967	Bannister	260	210	
	AD	3,313,801	Apr 11, 1967	Argoudelis <i>et al.</i>	260	210	
	AE	3,329,568	Jul 04, 1967	Argoudelis <i>et al.</i>	167	65	
	AF	3,359,164	Dec 19, 1967	Argoudelis <i>et al.</i>	167	65	
	AG	3,361,739	Jan 02, 1968	Argoudelis <i>et al.</i>	260	210	
	AH	3,395,139	Jul 30, 1968	Mason <i>et al.</i>	260	210	
	AI	3,475,407	Oct 28, 1969	Birkenmeyer	260	210	
	AJ	3,487,068	Dec 30, 1969	Morozowich <i>et al.</i>	260	210	
	AK	3,509,127	Apr 28, 1970	Kagan <i>et al.</i>	260	210	
	AL	3,513,155	May 19, 1970	Birkenmeyer <i>et al.</i>	260	210	
	AM	3,544,551	Dec 01, 1970	Kagan <i>et al.</i>	260	210	
	AN	3,580,904	May 25, 1971	Morozowich <i>et al.</i>	260	210	
	AO	3,655,885	Apr 11, 1972	Morozowich <i>et al.</i>	424	181	
	AP	3,676,302	Jul 11, 1972	Visser	195	80	
	AQ	3,705,889	Dec 12, 1972	Bannister <i>et al.</i>	260	210	
	AR	3,714,141	Jan 30, 1973	Shephard	260	210	
	AS	3,726,766	Apr 10, 1973	Argoudelis <i>et al.</i>	195	80	
	AT	3,812,014	May 21, 1974	Argoudelis <i>et al.</i>	195	80	
	AU	3,849,396	Nov 19, 1974	Birkenmeyer	260	210	
	AV	3,969,516	Jul 13, 1976	Stoughton	424	181	
	AW	4,031,304	Jun 21, 1977	Bannister	536	11	
	AX	RE 29,558	Feb 28, 1978	Bannister	536	11	
	AY	4,250,169	Feb 10, 1981	Hosoi <i>et al.</i>	424	181	
	AZ	4,271,266	Jun 02, 1981	Bergy <i>et al.</i>	435	73	
	BA	4,278,789	Jul 14, 1981	Birkenmeyer	536	11	
	BB	4,289,757	Sep 15, 1981	Glenn	424	120	
	BC	4,309,533	Jan 05, 1982	Birkenmeyer	536	11	
	BD	4,310,660	Jan 12, 1982	Birkenmeyer	536	11	
	BE	4,317,903	Mar 02, 1982	Hofstetter	536	11	
	BF	4,464,466	Aug 07, 1984	Argoudelis <i>et al.</i>	435	92	
	BG	4,568,741	Feb 04, 1986	Livingston	536	16.5	
	BH	4,710,565	Dec 01, 1987	Livingston <i>et al.</i>	536	16.5	

Examiner

Rachel Bennett

Date Considered

3/12/03

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

RECEIVED
 SEP 10 2002
 TECH CENTER 11630/2900
 Sheet 2 of 6

Form PTO-1449
 (Rev. 8-88)

U.S. Department of Commerce
 Patent and Trademark Office

Attorney Docket No.

Serial No.

6193/1

10/07/2002

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Pena *et al.*

Filing Date

February 5, 2002

Group No.

Unknown

U.S. PATENT DOCUMENTS

Examiner Initial*		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
RB	BI	4,732,753	Mar 22, 1988	Füller	424	85	
	BJ	4,765,978	Aug 23, 1988	Abidi <i>et al.</i>	424	80	
	BK	4,882,359	Nov 21, 1989	Nakagawa <i>et al.</i>	514	947	
	BL	5,436,009	Jul 25, 1995	Jauw <i>et al.</i>	424	436	
	BM	6,210,698	Apr 03, 2001	Yamazaki <i>et al.</i>	424	434	Apr 06, 2000
	BN	6,255,502	Jul 03, 2001	Penkler <i>et al.</i>	552	549	Apr 19, 1999
RB	BO	6,270,789	Aug 07, 2001	Sameshima <i>et al.</i>	424	433	Jan 19, 2000

FOREIGN PATENT DOCUMENTS

Examiner Initial*		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
RB	BP	0 206 947 B1	April 15, 1992	EPO	A61K	31/14		
	BQ	WO 87/01935	Apr 09, 1987	WIPO	A61K	7/48		
	BR	WO 88/04938	Jul 14, 1988	WIPO	A61K	47/00		
	BS	WO 88/09130	Dec 01, 1988	WIPO	A23K	1/17		
	BT	WO 89/04672	Jun 01, 1989	WIPO	A61K	47/00		
	BU	WO 96/34603	Nov 07, 1996	WIPO	A61K	31/34		
	BV	WO 96/39838	Dec 19, 1996	WIPO	A01N	57/00		
	BW	WO 97/44032	Nov 27, 1997	WIPO	A61K	31/415		
	BX	WO 98/14174	Apr 09, 1998	WIPO	A61K	9/14		
	BY	WO 98/50074	Nov 12, 1998	WIPO	A61K	45/00		
	BZ	WO 99/09964	Mar 04, 1999	WIPO (In German)	A61K	31/00		x
	CA	WO 99/29299	Jun 17, 1999	WIPO	A61K	9/02		
	CB	WO 00/72827	Dec 07, 2000	WIPO	A61K	9/16		
	CC	WO 01/10407	Feb 15, 2001	WIPO	A61K	9/02		
	CD	WO 01/37808	May 31, 2001	WIPO	A61K	9/14		
RB	CE	WO 02/03896	Jan 17, 2002	WIPO	A61F	6/06		

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

RB	CF	Antibiotics, List of Antibacterials Affecting Protein Synthesis, Lincosamides [online]. April 2001. Retrieved from the internet: <URL: http://www.bmb.leeds.ac.uk/mbiology/ug/ugteach/dental/antibiotics/dantibiobactprotlin.htm >.
----	----	---

Examiner

Date Considered

Rachel Bennett

3/12/02

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

RECEIVED
SEP 10 2002
TECHNICAL CENTER 160012908

Form PTO-1449 (Rev. 8-88)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 6193/1	Serial No. 10/072,492
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Pena et al.	
		Filing Date February 5, 2002	Group No. 1615 Unknown

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

CG	Birkenmeyer <i>et al.</i> Lincomycin, XI, Synthesis and Structure of Clindamycin, a Potent Antibacterial Agent. <i>J. Med. Chem.</i> , 13, pp. 616-619. (1970).
CH	Brown <i>et al.</i> Clindamycin Hydrochloride. In K. Florey, ed., <i>Analytical Profiles of Drug Substances</i> , Vol. 10, Academic Press, pp. 75-91. (1981).
CI	Chowhan <i>et al.</i> Suppository Bases (Semi-synthetic glycerides). In <i>Handbook of Pharmaceutical Excipients</i> , 1 st Ed., American Pharmaceutical Association and The Pharmaceutical Society of Great Britain, pp. 314-320. (1986).
CJ	Cleocin Vaginal Ovules. Pharmacia & Upjohn Co [online], September 24, 1999. Retrieved from the internet: <URL: www.pnu.com/products/pharm.asp >
CK	Coben <i>et al.</i> Suppositories. In Lachman <i>et al.</i> , ed., <i>The Theory and Practice of Industrial Pharmacy</i> , 3 rd Ed., Lea & Febiger, pp. 564-588. (1986).
CL	Gray <i>et al.</i> The Oral Toxicity of Clindamycin in Laboratory Animals. <i>Toxicol. Appl. Pharmacol.</i> , 21, pp. 516-531. (1972).
CM	Kapusnik-Uner <i>et al.</i> Chapter 47: Antimicrobial Agents (Continued). In Hardman <i>et al.</i> , ed. <i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i> , 9 th Ed., McGraw-Hill, pp. 1141-1143. (1996).
CN	Leigh. Antibacterial Activity and Pharmacokinetics of Clindamycin. <i>J. Antimicrob. Chemother.</i> , 7 (Supplement A), pp. 3-9. (1981).
CO	Lewis. Antiplasmodial Activity of 7-Halogenated Lincomycins. <i>The Journal of Parasitology</i> , 54, pp. 169-170. (1968).
CP	Lewis. Clinically Useful Antibiotics Obtained by Directed Chemical Modification-Lincomycins. <i>Federation Proceedings</i> , 33 (11), pp. 2303-2306. (1974).
CQ	Lincomycin, Summary Report 2. Committee for Veterinary Medicinal Products, The European Agency for the Evaluation of Medicinal Products. (July 2000).
CR	Lincosamides. Purdue Research Foundation [online], February 20, 1996. Retrieved from the internet: <URL: http://www.vet.purdue.edu/depts/bms/courses/chmr/linco.html >.
CS	Macrolides, Lincomycin and Clindamycin. <i>The Merck Manual of Diagnosis and Therapy</i> [online], 2001. Retrieved from the internet: <URL: http://www.merck.com/pubs/mmanual/section13/chapter153/153d.htm >.
CT	Magerlein <i>et al.</i> Chemical Modifications of Lincomycin. <i>Antimicrobial Agents and Chemotherapy</i> , pp. 727-736. (1966).
CU	Maurio. A Practical Guide to Antibacterial Agents: Macrolide Antibiotics. <i>American Clinical Laboratory</i> , pp. 12-13. (April 1997).
CV	McGehee <i>et al.</i> Comparative Studies of Antibacterial Activity In Vitro and Absorption and Excretion of Lincomycin and Clinimycin. <i>Am. J. Med. Sci.</i> , 256, pp. 279-292. (November 1968).
CW	McGregor. Bacterial Vaginosis is Associated with Prematurity and Vaginal Fluid Mucinas and Sialidase: Results of a Controlled Trial of Topical Clindamycin Cream. <i>American Journal of Obstetrics and Gynecology</i> , 170, pp. 1048-1060. (April 1994). Retrieved from the internet: http://gateway2.ovid.com/ovidw:b.cgi .
CX	The Merck Index, 12 th Ed., Merck & Co., pp. 397-398, 939-940, 1291. (1996).
CY	Oesterling. Aqueous Stability of Clindamycin. <i>J. Pharm. Sci.</i> , 59 (1), pp. 63-67. (January 1970).

Examiner: *Rachael Benult* Date Considered: *3/12/03*

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Mar-25-2004 03:42pm From: PATENT PFIZER ANN ARBOR MI 7346222026 T-079 P.008/014 F-042

PTQ/SE/DBA (08-03)

Approved for use thru Jan 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

Substitute for form 1448/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/072.492
--------------------	------------

Filing Date	February 5, 2002
-------------	------------------

First Named Inventor	Lorraine E. Pena, et al.
----------------------	--------------------------

Art Unit	1615
----------	------

Examiner Name	Rachel M. Hennert
---------------	-------------------

Attorney Docket Number	619372/US
------------------------	-----------

Sheet	1	of	1
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code ² Number * Kind Code ³ (if known)	MM-DD-YYYY			
CA		GB 1 219 700	01/20/1971	Upjohn Company		

Examiner Signature	<i>[Signature]</i>	Date Considered	4/22/2005
-----------------------	--------------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.